Mount Sinai Health System

A high-performance serologic assay test kit for SARS-CoV-2 antibodies developed by Kantaro Biosciences.

A genetic screening test designed to identify spinal muscular atrophy (SMA) early, allowing for earlier and more effective treatment of motor neuron destruction.

Precision diagnostics company focused on the detection and management of life-threatening food allergies.

A platform and suite of tests for the assessment of platelet reactivity to all major antiplatelet therapies such as aspirin, clopidogrel, prasugrel, and GP IIb/IIIa inhibitors.

Semi-quantitative SARS-CoV-2 serology test to detect the presence or absence of COVID-19 antibodies.

Vaccine platform company utilizing Newcastle Disease Virus (NDV) to induce neutralizing antibodies targeted at a range of emerging and pandemic viruses.

Highly targeted beam of UVB light to treat vitiligo, which is a long-term skin condition characterized by skin patches that have had pigment loss.

Custom-fit joint replacement manufactured using preoperative CT scans to create an exact anatomical fit for the shoulder joint.

3D printed custom implants for patients and a state-of-the-art robot that prepares the bones into which the implants are inserted.

Patient-optimized joint replacement implants designed to meet an individual patient’s anatomy as precisely as possible.

Carrier screening tool for the detection of spinal muscular atrophy (SMA) in silent carriers.

A lab and AI platform designed to receive digital scans and glass slides from pathologists and oncologists to produce and deliver reports with AI-powered insights.

Commercial clinical offering developed at Mount Sinai to understand how a patient is responding to organ transplant.

An epitope mapping platform providing an improved method for detecting, assessing, and monitoring food allergies in patients.

A blood test diagnostic portfolio designed to diagnose kidney rejection before clinical signs of kidney damage appear.

Digital therapeutic to treat major depressive disorder using Emotional Faces Memory Task (EFMT) technology.

A diagnostic aid that uses novel molecular biomarkers to assess the likelihood of ASD in children from birth to 18 months old, and to aid in diagnosis of ASD in patients aged 18 months to 21 years.

A digital program utilizing multidisciplinary care management in person and via telehealth to help patients build resilience to recover from inflammatory bowel disease challenges.

First-ever U.S. approved enzyme replacement therapy for Fabry disease, an inherited condition caused by genetic variation.

RNA interference therapy for acute hepatic porphyrias, developed with translational research support.

A clinic and research lab platform combining advanced medical diagnostic screening tools, digital applications, and data science to provide comprehensive health reports.

A family of protein kinase C modulators demonstrating effectiveness in improving lipid transport in Niemann-Pick Type C1 cells.

Esketamine CIII nasal spray received FDA approval in 2019 for patients of treatment-resistant depression and adults with major depressive disorder with acute suicidal ideation or behavior, in conjunction with an oral antidepressant.

An exoskeleton device designed to support patients to re-learn standing, weight shifting, and stepping patterns for walking, helping them improve speed, stamina, balance, and motor control.

A lower limb powered exoskeleton which enables therapists to offer task-specific and intensive gait training, as well as personal use in community or home settings.

First FDA-approved oral regimen that specifically helps to ease the moderate to severe pain that accompanies endometriosis.

A massive clinical trial platform for a single patient using engineered fruit fly tumor network models to evaluate FDA/NICE approved drugs for effective drug combinations.